Table 1.
Characteristics of the included studies.
| Genes | Study ID | Countries | Study design | Male (%) | Mean age (case/control) | Sample size (cases/controls) | Causality assessment | Diagnostic criteria | SNPs | Genotyping methods | Adjusted covariates | Treatment regimen used |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UGT1A1 | Kim 2009 | Korea | Matched case-control studya | 65.5 | 42.1/42.8 | 67/159 | NR | >2 ULN | rs3755319, rs2003569, rs4148323 | SNP-IT | Age, sex, baseline serum AST and ALT | HRZE |
| UGT1A1 | Chang 2012 | China, Taiwan | Case-control study | 67.3 | 60.4/53.4 | 17/81 | NR | >2 ULN | rs4148323, rs35350960, rs8175347, rs34946978 | PCR-RFLP | NR | HRZE |
| UGT1A1 | Chen 2016 | China | 1 : 4 matched case-control studyb | 73.0 | 43.7/43.6 | 89/356 | WHO-UMC | >2 ULN | rs4148323, rs8330 | TaqMan | Weight, hepatoprotectant use | HRZE(S) |
| UGT1A1 | Sun 2017 | China | 1 : 1 matched case-control studya | 61.5 | 38.2/38.9 | 461/466 | RUCAM | >5 ULN | rs4148323, rs4148326, rs4148328, rs12479045 | SNPscan | NR | HRZE |
| UGT1A1 | Tao 2018 | China | 1 : 2 matched case-control studyb | 75.5 | 47.5/47.5 | 290/580 | RUCAM | >2 ULN | rs2003569, rs887829, rs8330, rs3755319, rs4148328, rs11563250, rs4148323, rs6719561, rs4148329 | Sequenom MassARRAY | Weight, hepatoprotectant use | HRZE(S) |
| UGT1A3 | Kim 2009 | Korea | Matched case-control studya | 65.5 | 42.1/42.8 | 67/159 | NR | >2 ULN | rs2008584, rs6431625 | SNP-IT | Age, sex, baseline serum AST and ALT | HRZE |
| UGT1A4 | Zhu 2021 | China | 1 : 4 matched case-control studyc | 72.3 | 49.4/50.3 | 202/808 | RUCAM | >2 ULN | rs2011404 | Sequenom Mass array | Smoking, drinking, hepatoprotectant use, liver diseases | HRZE(S) |
| UGT1A6 | Hao 2011 | China | Case-control study | 80.0 | 47.1/45.0 | 202/239 | NR | >2 ULN | rs6759892, 308C/A, rs2070959 | PCR-RFLP | Smoking, drinking | 2HRZS(E)/4HR |
| UGT1A7 | Hao 2012 | China | Case-control study | 80.0 | 47.1/45.0 | 202/239 | NR | >2 ULN | rs17868323, rs17868324, rs11692021 | PCR-RFLP | Smoking, drinking | 2HRZS(E)/4HR |
| UGT2B4 | Chen 2021 | China | Case-control study | 59.6 | 49.4/50.3 | 118/628 | NR | >2 ULN | rs1131878, rs1966151, rs28361541, rs4557343, rs79407331 | iMLDR | NR | 2HRZE/4HR |
| UGT2B7 | Shi 2014 | China | Case-control study | 70.7 | 46.7/44.8 | 182/193 | NR | >2 ULN | rs7662029, rs7439366 | PCR-RFLP | Smoking, drinking | NR |
| UGT2B7 | Sun 2017 | China | 1 : 1 matched case-control studyd | NR | NR | 207/207 | NR | >3 ULN | rs7662029, rs7439366 | PCR-RFLP | NR | 2HRZS(E)/4HR |
| UGT2B7 | Chen 2017 | China | Case-control study | 39.7 | 32.8/38.9 | 24/223 | NR | >2 ULN | rs10028494, rs7668282 | Sequenom Mass array | Age, sex, BMI, smoking | 2HRZE/4HR |
NR, not report; PCR-RFLP, polymerase chain reaction and restriction fragment length polymorphism; WHO-UMC, World Health Organization-Uppsala Monitoring Centre system; RUCAM, Roussel Uclaf causality assessment method; SNPs, single nucleotide polymorphisms; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal; H, isoniazid; R, rifampicin; E, ethambutol; Z, pyrazinamide; S, streptomycin. aMatched with age and sex. bMatched with age (±5 years), sex, treatment history, disease severity, drug dosage, and place. cMatched with age (±5 years), sex, and treatment history. dMatched with sex and place.